二、研究背景 ECD 是一种罕见的组织细胞肿瘤，其特征为丝裂原活化蛋白激酶 - 细胞外信号调节激酶（MAPK - ERK [RAS - RAF - MEK - ERK]）通路中反复出现激活突变，其中 BRAF 突变最为常见。基于此，维莫非尼作为首个针对 BRAF V600E 突变的 ECD 靶向疗法获得美国 FDA 批准 ...

Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell ...

Well-characterized domains are Ras nanoclusters that may have a crucial control in input–output relationships in the Ras–Raf–MAPK/ERK kinase–ERK pathway. Distinct spatial domains can also ...

MAP2K1 mutations have been functionally classified into three groups according to their dependency on upstream RAS/RAF signaling. However, the clinical efficacy of mitogen-activated protein kinase ...

of the mitogen-activated protein kinase (MAPK) pathway, IMM-6-415, will be evaluated as an oral, twice-daily treatment. Patients with rapidly accelerated fibrosarcoma (RAF), kirsten rat sarcoma ...

NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

2006;2(4):180-181. The fact that PTC is associated with mutually exclusive alterations to MAPK pathway effectors offers intriguing therapeutic opportunities. Ras, RET and B-Raf are part of a ...